Bionaut Labs

Mr. Shpigelmacher is an accomplished manager of R&D projects and a robotics/AI expert. He has diverse general management experience including with the Israeli government, Primesense, McKinsey & Company, and Morgan Stanley. Mr. Shpigelmacher spent over six years at PDT Partners, a finance group spun out of Morgan Stanley, as a senior investment researcher creating proprietary investment strategies utilizing AI. He worked as an engagement manager at McKinsey, primarily serving clients in the healthcare and financial sectors. He also played a central role in the creation of Primesense, acquired by Apple. Prior to Primesense, he spent six years as a senior product manager for a sophisticated governmental R&D organization.

Dr. Kiseylov has 25 years of pharma and biotech R&D management experience, including drug discovery, preclinical and clinical development at the CHDI Foundation which focuses on treatments for Huntington’s disease, Amgen (oncology, ND diseases), Lilly, ChemDiv, and Genea Biocells.

On the forefront of pediatric neurosurgery research for more than 20 years, Dr. Loudon has conducted studies investigating molecular characterization and novel therapeutic approaches for CNS malignancy, cancer stem cell biology, and regenerative medicine. He is an integral member of the brain tumor program at CHOC Children’s Neuroscience Institute and the Hyundai Cancer Institute at CHOC Children’s where he is the brain tumor and stem cell research laboratory director. Dr. Loudon is director of neurotrauma of the level II trauma centre at CHOC and the Southern California Gamma Knife Center.

Medical device expert with over three decades of experience. Mr. Kardosh specializes in bringing revolutionary technology from ideation to safe and effective medical solutions.

Mr. Weissberg is a quality, operations, and R&D leader with experience in the development of new-to-the-world medical devices. He has held leadership positions with Medtronic, the Alfred E. Mann Institute for Biomedical Engineering, and successful start-ups in robotics and bioinformatics.

Dr. Jakobovits is an accomplished biotech executive in the area of targeted immunotherapy. She is the founder and CEO of Adicet bio, as well as the founding CEO of Kite Pharma (acquired by Gilead for $11.9B), CSO and SVP corporate development at Agensys, EVP and Head of R&D at Astellas/Agensys (acquired Agensys for $537M), and director and leader of XenoMouse technology at Cell Genesys/Abgenix (acquired by Amgen for $2.2B).

Dr. De Souza is a seasoned biotech executive and CNS expert. He served as SVP and US head of R&D for Aventis, as well as head of CNS at DuPont Merck. Dr. De Souza is the founder of Neurocrine and served as executive chairman at companies including Bionomics, Kures Inc., and nLife Therapeutics. He is also the former president and CEO of several public companies (Biodel; Synaptic Pharmaceutical Corp.) and private companies (Archemix; Neuropore).

Dr. Alpert is a worldwide expert in regulatory affairs with a focus on medical devices. She has held a variety of senior positions at the FDA, including as the director of the FDA’s Office of Device Evaluation. She has also held the positions of senior vice president and chief regulatory officer at Medtronic until 2012 and had a similar role at C.R. Bard.

For 20 years, Dr. Haffner served as director of the Office of Orphan Products Development (OOPD) of the FDA, responsible for the leadership and management of the FDA orphan products development program, the first orphan products program in the world. In addition to her FDA responsibilities, Dr. Haffner assisted in the development of orphan drug programs around the world including in the EU, Japan, and Australia.

Prof. Fischer is the inventor of the Bionaut technology. He has served as the head of the Micro, Nano and Molecular Systems Lab at Max Planck Institute for Intelligent Systems. Prof. Fischer is formerly a NATO postdoctoral fellow at Cornell, leader of research group at Harvard University, recipient of the Fraunhofer Attract award, as well as an European Research Council (ERC) grant holder.

Over fifteen years of experience in biopharma, medtech and digital health. Accomplished and successful entrepreneur. Passionate about solving challenging healthcare problems with large market opportunities and novel solutions. Demonstrated track record of closing large enterprise multi-year partnerships with top-30 pharma while driving significant upside value.